ABSTRACT
It has been known for more than 20 years that susceptibility to insulin-dependent diabetes mellitus (IDDM) has a very strong genetic component. Two major susceptibility regions have been identified in the human genome: the major histocompatibility complex (MHC) region on chromosome 6p21 (IDDM1) and the insulin gene region (IDDM2) on chromosome 11p15.5 (1) (2) (3) . In Caucasians, susceptibility to IDDM is strongly associated with HLA-DR3, -DR4 haplotypes, whereas resistance is associated with HLA-DR2. (4, 5) . In addition, certain HLA-DQB1, -DQA1, and DRB1 alleles confer susceptibility, whereas others provide resistance to disease (6, 7) . Recent studies have shown that differences of a few amino acid residues in DR4 alleles are sufficient to modify the risk of developing IDDM conferred by the high-risk DQA1*03-DQB1*0302 (DQ8) haplotype (8) (9) (10) . Among the HLA-DR4 alleles, DRB1*0405 confers the highest risk, DRB1*0401 has a higher risk than DRB1*0404, whereas DRB1*0403 confers a ''dominant'' protection even when the susceptible DRB1*0301-DQB1*0201 haplotype is present on the other chromosome (11, 12) .
IDDM2 maps to a variable number of tandem repeats (VNTR) minisatellite upstream of the insulin gene (INS) (13) . The short class I VNTR alleles (26-63 repeats) predispose to IDDM, whereas class III VNTR alleles (140-210 repeats) have a dominant protective effect (14, 15) . Interestingly, in multiplex IDDM families, IDDM2 class I VNTR alleles are transmitted preferentially to HLA-DR4-positive diabetic offspring, suggesting that the effect of the susceptibility gene(s) in IDDM2 is dependent on the presence of HLA-DR4 (16) .
The high level of insulin autoantibodies associated with expression of DR4 (17) and the early age of disease onset (18, 19) are consistent with this notion.
In the present study, using HLA-DRB1*0401 transgenic mice, we have found that the immunodominant epitopes restricted by this DR4 allele are located in the precursor forms of the hormone. These findings provide a possible explanation for how the insulin gene region-encoded susceptibility to type 1 diabetes is largely associated with HLA-DR4-positive individuals. We propose that one mechanism for susceptibility to IDDM may be that susceptible HLA-DR4 molecules present fragments of insulin and͞or its prohormones to CD4 ϩ T cells, thereby initiating an autoimmune response specifically targeted to the pancreatic ␤ cells. The identification of the PPI͞PI and Ins immunodominant T cell epitopes may provide tools for modulating or preventing diabetes in DR4-positive subjects.
METHODS
Generation of HLA-DR Transgenic Mice. All of the animals used in this study were bred and maintained at the research animal facility at Stanford University. HLA-DRB1*0401 mice co-expressing human CD4 were generated as described previously (20) . Transgenic mice expressing the DRB1*0401 allele and human CD4 on the DBA͞1J background were mated with I-A␤ gene, progeny were screened by anti-DR and anti-mouse CD4 double-staining FACSCAN analysis. CD4 T cell levels higher than 20% in peripheral blood lymphocytes were indicative of a homozygous state for the DRB1*0401 and human CD4 transgenes, as shown previously (22) Each construct was used to generate recombinant baculovirus using standard methods. PPI and PI were expressed in High Five cells (Invitrogen). Purification was achieved by Ni 2ϩ chelate affinity chromatography of a cleared lysate obtained from guanidine hydrochloride lysed cells infected for 3 days. Preparations were separated by SDS͞PAGE, and the specific band was visualized with KCl and purified to homogeneity by electroelution. Purity was checked by analytical SDS͞PAGE and by Western blot analysis using anti-insulin polyclonal antibodies (Biodesign).
Generation of T Cell Hybridomas. The DRB1*0401 ϩ/ϩ , human CD4 ϩ/ϩ , I-A␤ 0/0 mice were immunized in the footpads and at the base of the tail with 50 g of gel purified protein (PPI, PI) or with 50 g of Ins (Human recombinant, Sigma) emulsified in incomplete Freund's adjuvant (Difco). After 10 days, the draining lymph nodes were removed. Lymph node cells were resuspended at a concentration of 10 7 cells͞ml in complete medium (RPMI 1640, Bethesda Research Laboratories) containing 10% heat-inactivated fetal calf serum, 2 mM L-glutamine, 100 U͞ml penicillin, 100 g͞ml streptomycin, 50 M 2-mercaptoethanol, and Hepes and restimulated in vitro for 3 days with 10 g͞ml of gel-purified human PPI, PI, or Ins, using the same protein used for immunization. At the end of the stimulation period, cells were purified by Ficoll separation, washed, and restimulated with interleukin (IL)-2 conditioned complete medium for 24 h. Cells were then washed and fused to the TCR ␣-␤Ϫ variant of the BW5147 cell line, in 50% polyethylene glycol at a ratio of 1:3, and plated out in 96-well f lat bottom plates (20) . Hypoxanthine͞aminopterin͞ thymidine (HAT) medium was added at day 2 postplating, and the plates were incubated for 10 days. Growing hybridomas were expanded in 24-well plates prior to testing.
Generation of Overlapping Peptides. Preproinsulin peptides. A set of 10 overlapping peptides spanning the entire PPI sequence was synthesized by standard F-moc chemistry on an Applied Biosystem Peptide Synthesizer by the Protein and Nucleic Acid (PAN) Facility at Stanford University. To fine map each epitope, 33 overlapping 13-mer peptides were purchased from Research Genetics (Huntsville, AL) shifted by 3 amino acids, thus generating all possible decamers of PPI. In addition, to define the minimal core motif for the immuno- The purity of all these peptides was verified by reverse phase HPLC and mass spectroscopic analysis. Before use, the peptides were resuspended in sterile PBS at a concentration of 1 mg͞ml and stored at Ϫ20°C.
Assessment of Hybridoma Reactivity Using a EuropiumBased IL-2 Immunoassay. Antigen-presenting cells (APC).
Transgenic mouse spleen cells or typed Epstein-Barr virus (EBV) transformed B cells were washed in HAT medium (complete medium with HAT) and irradiated (spleen cells, 3000 rads; human lymphoblastoid B cells, 12,000 rads) with a cesium source. Antigens were added to 3 ϫ 10 5 irradiated transgenic APC or 1-3 ϫ 10 5 EBV cells per well, in a final volume of 50 l. Plated cells were incubated with antigen while the T cell hybridomas were prepared.
Antigen. Recombinant antigen purified by Ni 2ϩ columns was gel purified by electroelution of the relevant band and resuspended in PBS. Whole proteins were used at a concentration of 5-10 g͞ml.
T cell hybridomas. T cell hybridomas were washed, and 2-5 ϫ 10 4 cells in 100 l were added per well to the APCs.
IL-2 immunoassay. All antibody incubation and blocking steps were performed in blocking buffer (PBS͞1% BSA͞ 0.2% sodium azide) and all washes in wash buffer (PBS containing 0.05% Tween 20) . ELISA plates (Corning) were coated with rat anti-mouse IL-2 monoclonal antibody (PharMingen) at a concentration of 2 g͞ml by overnight incubation at 4°C. Plates were blocked for 3 h with blocking buffer, washed once, and incubated overnight at 4°C with 100 l of supernatant from a 48-h stimulation assay. Following five washes, biotinylated rat anti-mouse IL-2 monoclonal antibody (PharMingen) was added at a final concentration of 2 g͞ml in 100 l. After 2 h of incubation at room temperature, the plates were washed five times, and 100 l of 0.1 ng͞ml europium-labeled streptavidin was added. After 1 h, the plates were washed five times; 100 l of Enhancement solution (LKB-Wallac, Gaithersburg, MD) was added, and the plates were left for 5 min at room temperature. The resulting f luorescence was read using an LKB-Wallac f luorescence plate reader.
RESULTS
Details of the mice used for immunization have been described elsewhere (20, 22) . In brief, DRB1*0401-restricted T cell hybridomas were generated in mice lacking murine class II genes by crossing the I-A␤ null mutation onto HLA-DR4, human CD4 transgenic mice. Using these mice, we found that PPI and PI are strongly T cell immunogenic, whereas Ins is only weakly immunogenic for CD4-positive T cells (as distinct from the B cell antibody response). Table 1 shows the DRB1*0401-restricted T cell epitopes found in transgenic mice.
To identify specific hybridomas, T cell hybridomas were first tested using whole protein (PPI, PI, or Ins) and transgenic spleen cells as APC. Subsequently, the antigen-positive T cell hybridomas were tested using whole PPI, PI, insulin, or individual peptides and DRB1*0401-positive EBV (Preiss) cells as APCs. Figure 1 a-c shows the results of a representative T cell hybridoma, c 228. Figure 1a shows hybridoma c 228 responding to intact human insulin or human proinsulin using HLA DRB1*0401-positive transgenic spleen cells as APC. Figure 1b shows T cell hybridoma c 228 responding to a single peptide from a pool of 10 peptides using a human HLA DRB1*0401-positive EBV cell line as APC. The restriction element was determined by using anti-DR blocking antibody (L243) and DRB1*0401-expressing EBV cells (Preiss) as APC (Fig. 1c) . Isotypematched murine antibodies were used as a negative control (Fig. 1c) . Spleen cells from HLA DR␣1*0101, IA-␤ 0/0 transgenic mice, in which the only functional MHC class II heterodimer is the DR␣1*0101, IE-␤ chimeric molecule, were also used as APC to exclude participation of the chimeric class II molecule as a restriction element (see below).
The immunodominant epitope (p73-90) is located in a region spanning the C peptide and the A chain. The C peptide is absent in the mature hormone. In addition, responses to a number of other T cell epitopes were also found at low frequency: one peptide epitope was specific for the leader sequence (p11-26), another spanning part of the leader sequence and the B chain (p20 -36), and a fourth T cell epitope was recognized by a single T cell hybridoma, obtained after insulin immunization, specific for the insulin A chain (p85-101; Table 1 and Fig. 2) . These results demonstrate that the major T cell epitope of Ins or its prohormones presented by DRB1*0401 is located in the precursor forms of the hormone.
In the DRB1*0401 transgenic mice on the I-A␤ 0/0 background, the IE-␤ gene product can form a functional heterodimer with the human HLA-DR␣ chain. T cell hybridomas were identified that were specific for a peptide of the leader sequence (p1-18), and for a peptide spanning the junction of the insulin B chain and the C peptide (p40-59), both of which were restricted by the DR(␣1*0101), I-E␤ chimeric heterodimer (data not shown).
The core epitope sequence of the immunodominant p73-90 DRB1*0401 restricted peptide was identified using a Proc. Natl. Acad. Sci. USA 95 (1998) set of 9 N-or C-terminal truncated peptides. The response of T cell hybridoma, c 228, to these peptides is shown in Fig.  3 . The resulting minimal core epitope was found to be LALEGSLQK (Fig. 3a) . This peptide sequence is compatible with the DRB1*0401 peptide binding motifs recently published (24, 25) and with the model derived from the crystal structure of an inf luenza virus peptide (HA 306 -318) complexed with an HLA-DR1 molecule (26) . According to this model, the major anchor positions of the peptide with the HLA-DR peptide complex are found at peptide positions 1, 4, 6, 7, and 9 (26). The sequence LALEGSLQK contains a Leu as a large hydrophobic anchor residue at position P1. The specificity of the MHC pocket accommodating this residue is modulated by the Gly͞Val dimorphism at position 86 of the DR␤ chain. The protective DRB1*0403 allele has Val at this position, as opposed to the Gly of the susceptible DRB1*0401 (the transgenic allele used here) and DRB1*0405 alleles. The presence of a Val could potentially restrict the size or change the conformation of this pocket. The presence of a Lys at position DR␤-71 encoded by the DRB1*0401 allele has been shown probably to inf luence electrostatic interaction with the negatively charged Glu at position P4 of the peptide, whereas the presence of a Glu at position 74 of the DR␤-chain encoded by the protective DRB1*0403 allele (also contributing to pocket P4) would disfavor such an interaction. Pocket P6 is occupied by Ser, which is also found commonly in that position in other DRB1*0401 binding epitopes (22) .
The dose-response curve for the individual truncated peptides using T cell hybridoma c 228 (Fig. 3b) showed a similar response pattern to the truncated peptides for different p73-90 specific, DRB1*0401-restricted T cell hybridomas (results not shown).
DISCUSSION
Using this transgenic mouse model, we have identified one major immunodominant, naturally processed, DRB1*0401-restricted T cell epitope from human PPI͞PI in the region between the C peptide and the A chain. T cell responses to this peptide epitope have also been found in peripheral blood of HLA DRB1*0401-positive patients with recent onset type 1 diabetes (M.C. et al., unpublished results). Peptide p73-90 spans a region of the C peptide and the A chain of PI that is first cleaved by the endopeptidase II resulting in the split 64,65 proinsulin. Through removal of Lys and Arg (amino acid residues 64 and 65, respectively) by carboxypeptidase H, the intermediate des 64,65 proinsulin is generated. Thus, the last three amino acids of the PPI͞PI region peptide GAGSLQPLALEGSLQKR2G (the arrow indicates the endopeptidase II cleavage site, the minimal peptide sequence presented by DRB1*0401 is in boldface, and the two residues normally removed by carboxypeptidase H are underlined), removed by the cleavage of 64 -65 split proinsulin, exists under normal conditions only as a short-lived intermediate 
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Immunology: Congia et al. Proc. Natl. Acad. Sci. USA 95 (1998) during processing of the hormone in the granules of the ␤ cells.
Another epitope, p11-26, was located in the region spanning the leader peptide. The recognition of this epitope is even more intriguing because that epitope is present only when the PPI is still anchored to the endoplasmic reticulum. The presence of these DRB1*0401-restricted T cell epitopes indicates that precursors of insulin normally confined to the endoplasmic reticulum or the cytoplasm of the ␤ cell may be involved in targeting T cell autoreactivity to the islets.
Very recently, Pugliese and collaborators have shown that during fetal development and in childhood, mRNAs for insulin and other islet cell autoantigens (GAD, ICA69, IA-2) are expressed at low levels in the human thymus (27) . Proinsulin protein was detected in the thymus at levels four times higher than insulin (27) , suggesting that the possibility of a PI conversion into mature protein is unlikely. These authors and others (28) have found that VNTR class III alleles are associated with higher levels of proinsulin mRNA in the thymus, while homozygosity for class I VNTR alleles correlates with lower transcriptional activity. Under these circumstances, the higher levels of PI generated in the thymus (class III VNTR alleles) could promote negative selection of PI-specific T lymphocytes, which could play a critical role in protection from IDDM (27, 28) .
It is possible that in DRB1*0401-positive patients, IDDM2 class I alleles, which express lower levels of PPI͞PI proteins in the thymus, may result in a larger repertoire of autoreactive T cells specific for the DRB1*0401 immunodominant GAGSLQPLALEGSLQKR PPI͞PI peptide. The same class I VNTR alleles are associated in the pancreas with increased expression of PPI and PI (16, 17) . Thus, a viral infection or other exogenous damage to the ␤ cells of the islets may release increased amounts of the immunogenic portions of the hormone, which are located in the prohormones PI or PPI. Because the HLA-DR3 genotype is negatively correlated with the presence of anti-insulin autoantibodies (2, 29) . A scenario with a functional linkage between IDDM2 and a common HLA DR4 allele is an attractive possibility.
Additional evidence suggestive of a primary role for PPI and͞or PI expression in generating or deleting autoreactive T cells may be seen in the prevention of insulitis and diabetes in NOD mice by expression of mouse proinsulin II under the control of the MHC class II I-E␣ promoter in MHC class II positive cells (30) . Moreover, it has been reported that insulitis can be induced in rats receiving T cells specific for a proinsulin peptide sequence spanning the cleavage site between the B chain and the C peptide (31) . T cell reactivity against a peptide from the same proinsulin region has also recently been reported in individuals at risk for IDDM (32) .
The weaker T cell immunogenicity of Ins compared with the prohormones PPI and PI is consistent with the notion that T cell reactivity to mature insulin is rare in IDDM patients. It is generally acknowledged that T cell responses to insulin in IDDM patients are very much lower in frequency than T cell reactivity against GAD 65 or the tyrosine phosphatase ICA 512 (2) .
In summary these data indicate that one of the specific ␤ cell autoantigens involved in human IDDM is PPI and͞or PI. Our findings also provide a possible explanation for why the insulin gene region-encoded susceptibility to type 1 diabetes (IDDM2) is associated with HLA-DR4-positive patients. They also have important implications for the use of mature insulin in trial to prevent IDDM in prediabetics.
